Staff: Stephanie Land, Ph.D.
Stephanie Land, Ph.D.
stephanie.land@nih.gov
240-276-6946
Stephanie Land, Ph.D., (she/her/hers) is a Program Director and Statistician in the Behavioral Research Program Tobacco Control Research Branch (TCRB) at the National Cancer Institute (NCI). Her areas of focus are tobacco use among patients in the settings of cancer prevention, screening, treatment, and survivorship. She serves on the American Association for Cancer Research (AACR) Tobacco and Cancer Subcommittee and is chair of the NCI-AACR Cancer Patient Tobacco Use Assessment Task Force. Dr. Land is the NCI lead for the Smoking Cessation At Lung Examination (SCALE) Collaboration, a collaboration that will share data and methods across eight funded projects to pursue research on cessation interventions that are efficacious and feasible in lung cancer screening clinics. She is also the NCI lead for the Cancer Center Cessation Initiative (C3I) and the Director of Tools and Resources for the Society for Research on Nicotine and Tobacco (SRNT) - University. Dr. Land is a member of the National Lung Cancer Roundtable. Additionally, she is a member and past chair of the Division of Cancer Control and Population Sciences Clinical Trials Coordination Group. Formerly, she was a member of the NCI Special Studies Institutional Review Board, Associate Editor for the Journal of Clinical Oncology, and a member of the NCI Clinical Trials Stewardship Committee.
Before joining NCI in 2011, Dr. Land was co-founder and director of the Reduce Smoking and Exposure to Tobacco (ReSET) Center, an Associate Professor of Biostatistics at the University of Pittsburgh, and a member of the American Schools of Public Health Tobacco Use Council. She has twice served as principal investigator. In one project, she led an NCI-funded study on smoking and other lifestyle behaviors as predictors of patient adherence to chemoprevention in the setting of breast cancer. The second project was an intramurally funded study of tobacco use and social network formation during the first year of college.
Dr. Land has more than 100 research publications in print. From 1999-2011, she was a statistician in the National Surgical Adjuvant Breast and Bowel Project (NSABP), an NCI-funded clinical trials cooperative group that conducted multi-center phase III trials for breast and colorectal cancer. Her primary role in the NSABP was as the lead statistician for the Behavioral and Health Outcomes Program. She also collaborated with members of the University of Pittsburgh Cancer Institute Lung and Thoracic Malignancies Program from 1999-2011 and served as the lead statistician for the Lung Cancer Specialized Program of Research Excellence (SPORE) from 2002-11, directing the Core through two competing renewals. Before coming to NCI, Dr. Land participated in the Community Clinical Oncology Program (CCOP) Research Priorities Strategic Planning Committee (NCI), Subcommittee H (reviewing cooperative groups), the NCI Symptom Management and Quality of Life Scientific Steering Committee, and numerous NCI grant review panels. Dr. Land earned a doctorate in statistics from Stanford University.
Secondary Appointment: NCI Coordinating Center for Clinical Trials
Current and past mentors include Sarah Kobrin.
Current and/or past BRP mentees include Lia Sorgen and Leeann Siegel.
Research Areas
- Tobacco use and cessation among cancer patients
- Tobacco use and cancer prevention and screening
- Clinical trials
Selected Publications and Presentations
- Land SR, Baker L, Bachand J, Twesten J, Reyes-Guzman CM, Kaufman AR. Associations of Daily Versus Nondaily Smoking, Tobacco-Related Risk Perception, and Cancer Diagnosis Among Adults in the Population Assessment of Tobacco and Health (PATH) Study. Nicotine Tob Res 2022 Mar 4; ntac059.
- Kathuria H, Detterbeck FC, Fathi JT, Fennig K, Gould MK, Jolicoeur DG, Land SR, Massetti GM, Mazzone PJ, Silvestri GA, Slatore CG, Smith RA, Vachani A, Zeliadt SB, Wiener RS; ATS Assembly on Thoracic Oncology. Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2017 Nov 1; 196(9):1202-1212.
- Land SR, Warren GW, Crafts JL, Hatsukami DK, Ostroff JS, Willis GB, Chollette VY, Mitchell SA, Folz JN, Gulley JL, Szabo E, Brandon TH, Duffy SA, Toll BA. Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research. Cancer 2016 Jun 1; 122(11):1728-34.
- Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon TH, Prindiville SA, Sarna LP, Schnoll RA, Herbst RS, Cinciripini PM, Leischow SJ, Dresler CM, Fiore MC, Warren GW. Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. Clin Cancer Res 2016 Apr 15; 22(8):1907-13.
- Land SR, Walcott FL, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. J Natl Cancer Inst 2015 Nov 27; 108(4).
To request edits to this profile, please contact us at ncidccpsbrpadvances@mail.nih.gov.